Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice
Daxor Corporation (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces a new partnership with a leading hospital in North Carolina to integrate Daxor's BVA-100 blood volume measurement test as part of standard clinical practice. “Blood volume analysis allows us to provide a strategic and tactical approach to fluids, diuretics and transfusion in patients with complex illnesses that allows for improved mortality and morbidity as well as economic savings,” said Henry D. Cremisi, M.D., a specialist in nephrology & clinical research. "This new initiative began in the first quarter of the year and usage is accelerating as the hospital has seen the economic benefits of more efficient care and physicians have seen better results," said Michael Feldschuh, CEO of Daxor Corporation. "We are pleased to provide physicians with accurate, a
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA AnalyzerGlobeNewswire
- Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth SummitGlobeNewswire
- Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25GlobeNewswire
- Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSAGlobeNewswire
- Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting [Yahoo! Finance]Yahoo! Finance
DXR
Sec Filings
- 11/14/25 - Form 4
- 10/20/25 - Form N-2/A
- 10/15/25 - Form N-CSR/A
- DXR's page on the SEC website